Robert J Shulman1,2,3, Bruno P Chumpitazi1,2,3, Susan M Abdel-Rahman4, Uttam Garg5, Salma Musaad1,2, Gregory L Kearns6. 1. Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA. 2. Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA. 3. Texas Children's Hospital, Houston, TX, USA. 4. University of Missouri School of Medicine, Kansas City, MO, USA. 5. Departments of Pathology and Laboratory Medicine, Children's Mercy Hospital; University of Missouri School of Medicine, Kansas City, MO, USA. 6. Texas Christian University and University of North Texas Health Science Center School of Medicine, Fort Worth, TX, USA.
Abstract
AIMS: Little is known regarding the pharmacokinetics and pharmacodynamics of menthol, the active ingredient in peppermint oil (PMO). Our aim was to investigate the pharmacokinetics of menthol at 3 dose levels in children and determine their effects on gut motility and transit. METHODS: Thirty children ages 7-12 years with functional abdominal pain underwent wireless motility capsule (WMC) testing. Approximately 1 week later they were randomized to 180, 360 or 540 mg of enteric coated PMO (10 participants per dose). Menthol pharmacokinetics were determined via blood sampling over 24 hours. They then took their respective dose of PMO (180 mg once, 180 mg twice or 180 mg thrice daily) for 1 week during which time the WMC test was repeated. RESULTS: Evaluable area under the plasma concentration vs. time curve (AUClast ) data were available in 29 of 30 participants. A direct linear relationship (apparent dose-proportionality for systemic menthol exposure) was observed between PMO dose and menthol systemic exposure with mean elimination half-life 2.1, 3.5 and 4.6 hours for the 180, 360 and 540 mg doses, respectively. WMC technical issues precluded complete motility data in all participants. Colonic transit time was inversely related to AUClast (P = .003); transit time in other regions was not affected. In contrast, stomach, small bowel and whole gut (but not colonic) contractility positively correlated with menthol AUClast (P < .05). CONCLUSION: Pharmacokinetics and pharmacodynamics of menthol derived from PMO demonstrated apparent dose-proportionality. A higher dose of PMO may be needed to achieve maximal gut response. www.clinicaltrials.gov NCT03295747.
AIMS: Little is known regarding the pharmacokinetics and pharmacodynamics of menthol, the active ingredient in peppermint oil (PMO). Our aim was to investigate the pharmacokinetics of menthol at 3 dose levels in children and determine their effects on gut motility and transit. METHODS: Thirty children ages 7-12 years with functional abdominal pain underwent wireless motility capsule (WMC) testing. Approximately 1 week later they were randomized to 180, 360 or 540 mg of enteric coated PMO (10 participants per dose). Menthol pharmacokinetics were determined via blood sampling over 24 hours. They then took their respective dose of PMO (180 mg once, 180 mg twice or 180 mg thrice daily) for 1 week during which time the WMC test was repeated. RESULTS: Evaluable area under the plasma concentration vs. time curve (AUClast ) data were available in 29 of 30 participants. A direct linear relationship (apparent dose-proportionality for systemic menthol exposure) was observed between PMO dose and menthol systemic exposure with mean elimination half-life 2.1, 3.5 and 4.6 hours for the 180, 360 and 540 mg doses, respectively. WMC technical issues precluded complete motility data in all participants. Colonic transit time was inversely related to AUClast (P = .003); transit time in other regions was not affected. In contrast, stomach, small bowel and whole gut (but not colonic) contractility positively correlated with menthol AUClast (P < .05). CONCLUSION: Pharmacokinetics and pharmacodynamics of menthol derived from PMO demonstrated apparent dose-proportionality. A higher dose of PMO may be needed to achieve maximal gut response. www.clinicaltrials.gov NCT03295747.
Authors: Christopher J Black; Yuhong Yuan; Christian P Selinger; Michael Camilleri; Eamonn M M Quigley; Paul Moayyedi; Alexander C Ford Journal: Lancet Gastroenterol Hepatol Date: 2019-12-16
Authors: Michael Camilleri; Sanna McKinzie; Irene Busciglio; Phillip A Low; Seth Sweetser; Duane Burton; Kari Baxter; Michael Ryks; Alan R Zinsmeister Journal: Clin Gastroenterol Hepatol Date: 2008-05-05 Impact factor: 11.382
Authors: Miriam Spichiger; Roman C Mühlbauer; Rudolf Brenneisen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2004-01-05 Impact factor: 3.205
Authors: Rebecca N Cherry; Samra S Blanchard; Ashish Chogle; Neha R Santucci; Khyati Mehta; Alexandra C Russell Journal: Children (Basel) Date: 2022-08-22
Authors: Santosh Thapa; Ruth Ann Luna; Bruno P Chumpitazi; Numan Oezguen; Susan M Abdel-Rahman; Uttam Garg; Salma Musaad; James Versalovic; Gregory L Kearns; Robert J Shulman Journal: Clin Transl Sci Date: 2022-01-20 Impact factor: 4.438